anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

207,181-207,240 of 319,975

filter-aware
11
Includes a footnote explaining the composition of 'Financial income, net'.Talkspace | Results Presentation Deck | 11 slides · Talkspace
Conference presentation Investor relations 1 hit
01
Slide 1
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
02
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
03
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
04
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
05
Uses a before-after framing to show alignment between stated goals and actual performance.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
06
Uses a before-after framing to show goal alignment.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
07
Uses a simple before-after framing to track progress against specific financial goals.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
08
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
09
The slide uses two bar charts to demonstrate growth in both financial and volume metrics.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
10
The slide uses a line chart for hospital share and a combo bar/line chart for community share.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
11
The chart uses a highlighted bar for the most recent quarter (2023-Q1) to emphasize the record-high performance.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
12
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
13
The slide uses a before-after structure to justify a design change based on patient sub-grouping.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
14
The slide outlines a clinical trial methodology including randomization, treatment duration, and primary/secondary endpoints.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
15
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
16
Includes company branding and study logo.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
17
The slide uses a before-after framework to illustrate the physiological impact of the drug.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
18
Uses a before-after framing to explain the mechanism of action for Ampreloxetine.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
19
The slide uses a process-flow layout to connect mechanism to clinical outcomes.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
20
The chart is a forest plot showing LS Mean differences with 95% confidence intervals for various OHQ questionnaire scores.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
21
The slide outlines a clinical trial methodology using a randomized withdrawal design.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
22
The slide uses a combination of market sizing metrics and a competitive product comparison table.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
23
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
24
Includes GAAP and non-GAAP financial data.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
25
Includes per share data and share counts for basic and diluted calculations.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
26
The slide emphasizes the company's improved financial position, specifically the reduction in debt and share buybacks.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
27
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
28
The chart shows a significant reduction in operating expenses from 2020 to 2023 guidance.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
29
Uses a timeline-like arrow structure to represent progression of value drivers.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
30
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
31
Standard pharmaceutical product disclosure slide.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
32
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
33
Theravance Biopharma | Results Presentation Deck | 41 slidesTheravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
34
Includes definitions for COPD, nOH, and PTE in the footer.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
35
The slide uses a mathematical formula structure to explain revenue recognition.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
36
The table displays projected royalties and milestones for 2023-2026, while the right side details royalty return dates for 2029 and 2031.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
37
The slide uses two distinct colored containers to contrast the two different drug deal structures.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
38
Uses a funnel diagram to illustrate market penetration.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
39
Slide 39 of a presentation deck.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
40
The slide contrasts a narrow 'dizziness' focus with a broader 'constellation of symptoms' approach for MSA patients.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
41
The slide uses a three-column layout to categorize achievements into product, clinical, and financial pillars.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
01
Slide 1
UBS | Mergers and Acquisitions Presentation Deck | 11 slidesUBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
02
UBS | Mergers and Acquisitions Presentation Deck | 11 slidesUBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
03
Standard regulatory disclosure slide detailing IFRS 3 and SEC Regulation S-X compliance.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Loop · Cost Of Inaction1 hit
04
UBS | Mergers and Acquisitions Presentation Deck | 11 slidesUBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Loop · Cost Of Inaction1 hit
05
The slide uses a waterfall bridge to reconcile equity adjustments between two entities.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
06
The table highlights that these adjustments are CET1 neutral.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
07
The slide provides a breakdown of mark-downs and mark-ups for various asset classes, including loans, real estate, and software, following IFRS 3 acquisition rules.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
08
The table breaks down impacts on Assets, Liabilities, Equity, and CET1 capital.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
09
The chart bridges Credit Suisse equity to pro forma negative goodwill via transaction adjustments.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
10
This is a financial disclosure table detailing the accounting adjustments made during the Credit Suisse acquisition.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Beat · FinancialsLoop · Cost Of Inaction1 hit
11
Standard regulatory filing boilerplate.UBS | Mergers and Acquisitions Presentation Deck | 11 slides · UBS
Regulatory filing Investment bank Loop · Cost Of Inaction1 hit
01
Slide 1
Vivid Seats | Results Presentation Deck | 20 slidesVivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
02
The slide features a baseball player image, likely a metaphor for 'hitting it out of the park' or performance.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
03
Vivid Seats | Results Presentation Deck | 20 slidesVivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
04
Vivid Seats | Results Presentation Deck | 20 slidesVivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations Beat · Problem1 hit
05
The slide uses a process-flow visual to connect three key financial metrics.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
06
2020 data is omitted due to COVID-19 pandemic.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
07
Vivid Seats | Results Presentation Deck | 20 slidesVivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit